Re: IBRX, this release today. Positive phase 2 data in lung cancer, let's land a phase 3.
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
September 8, 2025
PDF Version
Severe lymphopenia, an adverse treatment effect associated with chemotherapy, radiotherapy, and immunotherapy, significantly lowers overall survival in non-small cell lung cancer and multiple types of cancer.1,2
With ANKTIVA, the first FDA-approved lymphocyte-stimulating agent, 80% of patients exceeded or maintained absolute lymphocyte count (ALC) above 1,000 cells/µL.
With ALC counts greater than 1,500 cells/µL, statistically significant prolonged median overall survival (OS) of 21.1 months occurred with patients alive ranging as long as over 4 years in stark contrast to the historical 7 to 9 months survival with docetaxel in these patients with advanced lung cancer.
Findings from the Phase 2 QUILT-3.055 study presented at IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain represent a paradigm change in a chemotherapy-free treatment of lung cancer by activating Natural Killer cells and T cells, the lymphocytes key to inducing cancer cell death.
Patients are currently being enrolled in the randomized Phase 3 ResQ201A trial (NCT06745908), which is evaluating ANKTIVA + tislelizumab, a checkpoint inhibitor versus docetaxel alone in second-line NSCLC patients who have progressed after all standard therapies, including checkpoint inhibitors.